18 results on '"Song, Kevin"'
Search Results
2. Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population.
3. Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center.
4. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
5. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
6. P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
7. P-189: Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma (MM-014 phase 2 trial): a subanalysis of patients previously treated with lenalidomide and a proteasome inhibitor.
8. P-120: Improving the risk stratification of multiple myeloma with a nucleotide editor/inflammation-based scoring system.
9. Health-Related Quality of Life With Pomalidomide + Dexamethasone + Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients.
10. Maintenance therapy with either Lenalidomide or Bortezomib equally improves PFS and OS in High Risk Myeloma initially treated with Autotransplant.
11. The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting.
12. Phase 3 FIRST Trial in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Patients From Canada and the United States.
13. Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study.
14. The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685).
15. Evaluating the Role of Tregs in the Progression of Multiple Myeloma.
16. Phase 2 Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and Safety.
17. Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM).
18. Effect of Treatment with Lenalidomide Plus Low-Dose Dexamethasone Until Progression on Health-Related Quality of Life Over Time in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.